Ginkgo biloba does not improve cognitive function in MS A randomized placebo-controlled trial

Neurology

Volumn 79, Issue 12, 2012, Pages 1278-1284

  Lovera, Jesus F ^a   Kim, Edward ^b,e   Heriza, Elizabeth ^b   Fitzpatrick, Mary ^b   Hunziker, James ^c   Turner, Aaron P ^c,d   Adams, Joshua ^b   Stover, Thomas ^c   Sangeorzan, Adam ^c   Sloan, Alicia ^c   Howieson, Diane ^e   Wild, Katherine ^e   Haselkorn, Jodie ^c,d   Bourdette, Dennis ^b,e  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c Puget Sound Health Care System   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; GINKGO BILOBA EXTRACT; GLATIRAMER; INTERFERON BETA SERINE; METHOTREXATE; MITOXANTRONE; MYCOPHENOLIC ACID; NATALIZUMAB; PLACEBO;

ADULT; ARTICLE; CALIFORNIA VERBAL LEARNING TEST 2; COGNITION; COGNITIVE DEFECT; CONTROLLED ORAL WORD ASSOCIATION TEST; CONTROLLED STUDY; DRUG SAFETY; FEMALE; FOLLOW UP; GINKGO BILOBA; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PERFORMANCE; MULTIPLE SCLEROSIS; NEUROPSYCHOLOGICAL TEST; OUTCOME ASSESSMENT; PACED AUDITORY SERIAL ADDITION TASK; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; STROOP TEST; UNSPECIFIED SIDE EFFECT;

EID: 84867566612     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31826aac60     Document Type: Article

References (28)

1. Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 1991;41:685-691.
2. Amato MP, Ponziani G, Siracusa G, Sorbi S. Cognitive dysfunction in early-onset multiple sclerosis: A reappraisal after 10 years. Arch Neurol 2001;58:1602-1606.
3. Benedict RH, Cookfair D, Gavett R, et al. Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc 2006;12:549-558.
4. Benedict RH, Zivadinov R. Risk factors for and management of cognitive dysfunction in multiple sclerosis. Nat Rev Neurol 2011;7:332-342.
5. Harel Y, Appleboim N, Lavie M, Achiron A. Single dose of methylphenidate improves cognitive performance in multiple sclerosis patients with impaired attention process. J Neurol Sci 2009;276:38-40.
6. Sumowski JF, Chiaravalloti N, Erlanger D, Kaushik T, Benedict RH, Deluca J. L-Amphetamine improves mem- ory in MS patients with objective memory impairment. Mult Scler 2011;17:1141-1145.
7. Morrow SA, Kaushik T, Zarevics P, et al. The effects of L-amphetamine sulfate on cognition in MS patients: Results of a randomized controlled trial. J Neurol 2009;256: 1095-1102.
8. Benedict RH, Munschauer F, Zarevics P, et al. Effects of L-amphetamine sulfate on cognitive function in multiple sclerosis patients. J Neurol 2008;255:848-852.
9. Kooi EJ, Prins M, Bajic N, et al. Cholinergic imbalance in the multiple sclerosis hippocampus. Acta Neuropathol 2011;122:313-322.
10. Krupp LB, Christodoulou C, Melville P, et al. Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis. Neurology 2011;76:1500-1507.
11. Srinivasan R, Sailasuta N, Hurd R, Nelson S, Pelletier D. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain 2005;128: 1016-1025.
12. Newcombe J, Uddin A, Dove R, et al. Glutamate receptor expression in multiple sclerosis lesions. Brain Pathol 2008; 18:52-61.
13. Pampliega O, Domercq M, Soria FN, Villoslada P, Rodriguez-Antiguedad A, Matute C. Increased expression of cystine/glutamate antiporter in multiple sclerosis. J Neuroinflammation 2011;8:63.
14. Lovera JF, Frohman E, Brown TR, et al. Memantine for cognitive impairment in multiple sclerosis: A randomized placebo-controlled trial. Mult Scler 2010;16:715-723.
15. Villoslada P, Arrondo G, Sepulcre J, Alegre M, Artieda J. Memantine induces reversible neurologic impairment in patients with MS. Neurology 2009;72:1630-1633.
16. Bazan NG. The neuromessenger platelet-activating factor in plasticity and neurodegeneration. Prog Brain Res 1998; 118:281-291.
17. Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2009:CD003120.
18. Yadav V, Shinto L, Morris C, Senders A, Baldauf-Wagner S, Bourdette D. Use and self-reported benefit of complementary and alternative medicine among multiple sclerosis patients. Int J MS Care 2006;8:5-10.
19. Lovera J, Bagert B, Smoot K, et al. Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis: A randomized, placebo-controlled trial. Mult Scler 2007;13:376-385.
20. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001;50:121-127.
21. Spreen O, Strauss E. A Compendium of Neuropsychological Tests, 1st ed. New York: Oxford University Press; 1991.
22. Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test Manual: Second Edition, Adult Version. San Antonio, TX: Psychological Corporation; 2000.
23. PASAT Manual [online]. Available at: Http://www.pasat.us/PDF/PASAT- Manual.pdf. Accessed March 16, 2012.
24. Sullivan J, Edgley K, Dehoux E. A survey of multiple sclerosis: Part 1: Perceived cognitive problems and compensatory strategy use. Can J Rehab 1990;4:99-105.
25. Benedict RH, Zivadinov R. Predicting neuropsychological abnormalities in multiple sclerosis. J Neurol Sci 2006;245: 67-72.
26. Willer B, Ottenbacher KJ, Coad ML. The community integration questionnaire: A comparative examination. Am J Phys Med Rehabil 1994;73:103-111.
27. Fisk JD, Ritvo PG, Ross L, Haase DA, Marrie TJ, Schlech WF. Measuring the functional impact of fatigue: Initial validation of the fatigue impact scale. Clin Infect Dis 1994;18(suppl 1):S79-S83.
28. Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory-II. San Antonio, TX: Psychological Corporation; 1996.